October 3, 2019 – Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent Sapien 3 transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR.
Findings were reported at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Two-year results from the PARTNER 2A trial concluded that TAVR was similar to surgery for the primary endpoint of death or disabling stroke in patients with severe AS and intermediate surgical risk. However, there are limited data on longer-term clinical outcomes and bioprosthetic valve function in this population. The goal of the current trial was to compare the key clinical outcomes, bioprosthetic valve function, and quality-of-life measures at five years for TAVR versus surgery.
Researchers randomly assigned 2,032 intermediate-risk patients with severe AS to either TAVR or SAVR at 57 centers. The two-year primary endpoint was all-cause death or disabling stroke in the intention to treat (ITT) population. At five years, all primary and secondary clinical and echo endpoints were analyzed in both ITT and pre-specified as-treated (AT) populations.
At five years, event rates for the primary endpoint of death or disabling stroke were 47.9% after TAVR and 43.4% after SAVR (HR: 1.09; 95% CI: 0.95 to 1.25; P=0.21). In the transfemoral cohort, there also was no difference at five years (44.5% TAVR versus 42.0% SAVR; HR: 1.02; 95% CI: 0.87 to 1.20; P=0.80).
However, in the transthoracic cohort, the rate of death or disabling stroke was significantly higher after TAVR (59.3% versus 48.3%; HR: 1.32; 95% CI: 1.02 to 1.71; P=0.03). In addition, early improvements in functional status and quality of life were maintained through five years for both TAVR and SAVR patients.
“In the longest follow-up for intermediate-risk patients with severe AS, TAVR and SAVR had similar rates of death or disabling stroke,” said Vinod H. Thourani, M.D., chair of the Department of Cardiac Surgery at Medstar Heart and Vascular Institute. “Therefore, TAVR should be considered as an alternative to surgery in intermediate-risk patients with severe aortic stenosis. However, in patients without acceptable transfemoral access, surgery may be the preferred alternative.”
The PARTNER 2A study was funded by Edward Lifesciences. Dr. Thourani disclosed grant/research support from Edwards Lifesciences, Abbott Vascular, Boston Scientific, JenaValve and Cryolife; sitting on Steering Committees for Edwards Lifesciences, Abbott Vascular, Boston Scientific, JenaValve, Cryolife and Gore Vascular; and honoraria from Edwards Lifesciences, Abbott Vascular, Boston Scientific,JenaValve, Cryolife, and Gore Vascular.
Find information on other late-breaking TCT trials
Related PARTNER TAVR Trial Content:
TAVR Cost-Effective Compared With SAVR in Intermediate-Risk Aortic Stenosis Patients
Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study
TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
FDA Approves TAVR for Low-risk Patients Creates A Paradigm Shift in Cardiology
National Coverage Determination Will Make TAVR Available to More Patients at More Centers
August 25, 2025 
